ACE and type 2 diabetes mellitus: While individual studies reported controversial results regarding the effect of angiotensin-converting enzyme (ACE) inhibitors/ARBs on CV risk in hypertensive patients with type II diabetes mellitus (DMII), a meta-analysis of randomized control studies concluded that this class of drug is associated with significant reduction in CV events and mortality (Hao et al., 2014).